Glen J. Weiss

419 total citations
9 papers, 143 citations indexed

About

Glen J. Weiss is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Glen J. Weiss has authored 9 papers receiving a total of 143 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Molecular Biology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Glen J. Weiss's work include Cancer therapeutics and mechanisms (2 papers), Neutropenia and Cancer Infections (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Glen J. Weiss is often cited by papers focused on Cancer therapeutics and mechanisms (2 papers), Neutropenia and Cancer Infections (2 papers) and Drug Transport and Resistance Mechanisms (2 papers). Glen J. Weiss collaborates with scholars based in United States, Switzerland and Germany. Glen J. Weiss's co-authors include Daniel D. Von Hoff, Rajesh Ramanathan, Ramesh K. Ramanathan, Gregory N. Dietsch, Kristi L. Manjarrez, Peter A. Cohen, Donald W. Northfelt, Robert M. Hershberg, J. Jac and Anthony W. Tolcher and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Glen J. Weiss

9 papers receiving 138 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Glen J. Weiss United States	6	76	57	44	28	21	9	143
Isabel Weinhäuser Brazil	5	49 0.6×	110 1.9×	62 1.4×	21 0.8×	32 1.5×	19	217
David Sommerhalder United States	7	66 0.9×	89 1.6×	29 0.7×	10 0.4×	47 2.2×	43	162
Claire H. Barnes France	2	55 0.7×	86 1.5×	16 0.4×	7 0.3×	35 1.7×	2	137
Oliver Krieter Switzerland	9	113 1.5×	139 2.4×	53 1.2×	6 0.2×	22 1.0×	25	215
Mark R. Nathan United Kingdom	3	71 0.9×	93 1.6×	23 0.5×	6 0.2×	56 2.7×	5	202
Emily S. Humphrey Australia	5	48 0.6×	91 1.6×	15 0.3×	11 0.4×	12 0.6×	5	151
Devora Delman United States	6	72 0.9×	91 1.6×	44 1.0×	5 0.2×	16 0.8×	8	188
Kate Anderton United Kingdom	4	36 0.5×	119 2.1×	20 0.5×	37 1.3×	12 0.6×	8	193
M. Jevric Serbia	5	48 0.6×	40 0.7×	23 0.5×	13 0.5×	16 0.8×	12	111
Leslie Hall United States	4	70 0.9×	104 1.8×	10 0.2×	98 3.5×	74 3.5×	7	211

Countries citing papers authored by Glen J. Weiss

Since Specialization

Citations

This map shows the geographic impact of Glen J. Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glen J. Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glen J. Weiss more than expected).

Fields of papers citing papers by Glen J. Weiss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glen J. Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glen J. Weiss. The network helps show where Glen J. Weiss may publish in the future.

Co-authorship network of co-authors of Glen J. Weiss

This figure shows the co-authorship network connecting the top 25 collaborators of Glen J. Weiss. A scholar is included among the top collaborators of Glen J. Weiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Glen J. Weiss. Glen J. Weiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Jaminet, Shou-Ching, et al.. (2025). AGX101: A TM4SF1-directed tubulin inhibitor conjugate in ongoing first-in-human trial including GI cancers.. Journal of Clinical Oncology. 43(4_suppl). 829–829. 1 indexed citations

Disis, ML, E.P. Hamilton, A. Craig Lockhart, et al.. (2015). 2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity. European Journal of Cancer. 51. S546–S547. 9 indexed citations

Patnaik, Amita, Glen J. Weiss, K. Papadopoulos, et al.. (2014). Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. British Journal of Cancer. 111(2). 272–280. 37 indexed citations

Northfelt, Donald W., Ramesh K. Ramanathan, Peter A. Cohen, et al.. (2014). A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma. Clinical Cancer Research. 20(14). 3683–3691. 45 indexed citations

Patnaik, Amita, Ramesh K. Ramanathan, Leonard J. Appleman, et al.. (2012). Phase I Study of Intravenous PI3K Inhibitor Bay 80–6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort. Blood. 120(21). 3704–3704. 11 indexed citations

Dickson, Natalie R., Suzanne F. Jones, H. A. Burris, et al.. (2011). A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment.. Journal of Clinical Oncology. 29(15_suppl). 2607–2607. 29 indexed citations

Weiss, Glen J., Michael Gordon, Lee S. Rosen, et al.. (2010). Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.. Journal of Clinical Oncology. 28(15_suppl). 2576–2576. 4 indexed citations

Ramanathan, Ramesh K., Francis Payumo, Kyriakos P. Papadopoulos, et al.. (2009). Abstract A100: A phase 1, first in human, study of SCH 900105, an antihepatocyte growth factor (HGF) monoclonal antibody, in subjects with advanced solid tumors. Molecular Cancer Therapeutics. 8(12_Supplement). A100–A100. 6 indexed citations

Rosen, Lee S., et al.. (2009). A phase I study of daily oral TRC102 (methoxyamine) to enhance the therapeutic effects of pemetrexed in patients with advanced refractory cancer. Journal of Clinical Oncology. 27(15_suppl). 2552–2552. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact